Ditchcarbon
  • Customers
  1. Organizations
  2. Ucb
Public Profile
Pharmaceutical Preparation Manufacturing
BE
updated 9 days ago

Ucb

Company website

UCB, or UCB S.A., is a global biopharmaceutical company headquartered in Belgium. Founded in 1928, UCB has established itself as a leader in the biopharmaceutical industry, focusing on the development of innovative therapies for neurological and immunological disorders. With a strong presence in Europe and North America, UCB is dedicated to improving the lives of patients through its core products, including treatments for epilepsy, Parkinson's disease, and autoimmune conditions. The company is renowned for its commitment to research and development, which has led to significant milestones such as the launch of several groundbreaking therapies. UCB's unique approach combines advanced science with patient-centric solutions, positioning it as a key player in the global healthcare market. With a robust pipeline and a focus on unmet medical needs, UCB continues to make notable strides in the biopharmaceutical landscape.

DitchCarbon Score

How does Ucb's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

95

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

28

Industry Benchmark

Ucb's score of 95 is higher than 97% of the industry. This can give you a sense of how well the company is doing compared to its peers.

97%

Let us know if this data was useful to you

Ucb's reported carbon emissions

In 2024, UCB reported total carbon emissions of approximately 790,866,000 kg CO2e, with significant contributions from Scope 1, 2, and 3 emissions. Specifically, Scope 1 emissions accounted for about 21,718,000 kg CO2e, while Scope 2 emissions were approximately 16,291,000 kg CO2e (location-based). The majority of emissions stemmed from Scope 3, totalling around 769,143,000 kg CO2e, which includes substantial figures from purchased goods and services (about 692,013,000 kg CO2e) and business travel (approximately 24,873,000 kg CO2e). UCB has set ambitious climate commitments, aiming to reduce absolute Scope 1 and 2 GHG emissions by 73% by 2030 from a 2019 base year, and to achieve net-zero emissions across all scopes by 2045. Additionally, UCB targets a 90% reduction in absolute Scope 1, 2, and 3 emissions by 2045 compared to the same 2019 baseline. The company also commits that 60% of its suppliers by emissions will have science-based targets by 2025. These targets align with the Science Based Targets initiative (SBTi) and reflect UCB's commitment to addressing climate change within the pharmaceutical and biotechnology sector. The company is headquartered in Belgium and operates with a focus on sustainability and environmental responsibility.

Unlock detailed emissions data

Access structured emissions data, company-specific emission factors, and source documents

201320142015201620172018201920202021202220232024
Scope 1
34,733,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
Scope 2
31,367,000
00,000,000
0,000,000
00,000,000
0,000,000
0,000,000
00,000,000
0,000,000
0,000,000
0,000,000
00,000,000
0,000
Scope 3
-
-
000,000,000
00,000,000
00,000,000
00,000,000
00,000,000
000,000,000
000,000,000
000,000,000
00,000,000
000,000,000

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Ucb's primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Ucb is in BE, which has a very low grid carbon intensity relative to other regions.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Ucb is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Similar Organizations

Life Technologies Corporation

US
•
Pharmaceutical Preparation Manufacturing
Updated 12 days ago

Celltrion

KR
•
Pharmaceutical Preparation Manufacturing
Updated 3 days ago

Amgen

US
•
Pharmaceutical Preparation Manufacturing
Updated 3 days ago

Sandoz

CH
•
Pharmaceutical Preparation Manufacturing
Updated 3 days ago

Teva Pharmaceuticals

IL
•
Pharmaceutical Preparation Manufacturing
Updated 3 days ago

Sigma-Aldrich Corporation

US
•
Pharmaceutical Preparation Manufacturing
Updated 8 days ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers

Ditchcarbon
v250807.3
enquiries@ditchcarbon.com+44 203 475 7875Ditch Carbon Ltd167-169 Great Portland StreetLondon W1W 5PF
Verified byUL Verified
Partnered withCDP
ProductPortalDataDocumentationIntegrationsChangelogPricing
SolutionsProcurement teamsSustainability teamsPlatform ownersCarbon accountants
ResourcesMethodologyBlogFAQOrganizationsIndustriesSBTI APITrust Centre
AboutTeamCareersLicense AgreementPrivacy